GÜNEŞ, E. Et Al. 2018. Primary adrenal failure and hypothyroidism adverse effect with nivolumab immuno‐oncology agent. JEMDSA Vol 23(3) 2019 Supp S144-145. 18th International Congress of Endocrinology, 53rd Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) Congress .

GÜNEŞ, E., CANDER, S., ÖZ GÜL, Ö., & ERSOY, C., (2018). Primary adrenal failure and hypothyroidism adverse effect with nivolumab immuno‐oncology agent. JEMDSA Vol 23(3) 2019 Supp S144-145 . 18th International Congress of Endocrinology, 53rd Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) Congress

GÜNEŞ, ELİF Et Al. "Primary adrenal failure and hypothyroidism adverse effect with nivolumab immuno‐oncology agent. JEMDSA Vol 23(3) 2019 Supp S144-145," 18th International Congress of Endocrinology, 53rd Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) Congress, 2018

GÜNEŞ, ELİF Et Al. "Primary adrenal failure and hypothyroidism adverse effect with nivolumab immuno‐oncology agent. JEMDSA Vol 23(3) 2019 Supp S144-145." 18th International Congress of Endocrinology, 53rd Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) Congress , 2018

GÜNEŞ, E. Et Al. (2018) . "Primary adrenal failure and hypothyroidism adverse effect with nivolumab immuno‐oncology agent. JEMDSA Vol 23(3) 2019 Supp S144-145." 18th International Congress of Endocrinology, 53rd Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) Congress .

@conferencepaper{conferencepaper, author={ELİF GÜNEŞ Et Al. }, title={Primary adrenal failure and hypothyroidism adverse effect with nivolumab immuno‐oncology agent. JEMDSA Vol 23(3) 2019 Supp S144-145}, congress name={18th International Congress of Endocrinology, 53rd Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) Congress}, city={}, country={}, year={2018}}